EUVIMEDEUVIMED entdecken
Crossref

The Clinical Relevance of the Expression of SGLT2 in Lung Adenocarcinoma

Shun Iwai, Nozomu Motono, Tsunehiro Oyama, Akihiro Shioya, Sohsuke Yamada, Hidetaka Uramoto

Oncology · 2024 · 102 (8) · 710-719

DOI: 10.1159/000536060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, online erschienen am 17.01.2024. Verfasst von Shun Iwai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Kanazawa Medical University, Uchinada-machi, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung, Sodium-Glucose Transporter 2. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

We aimed to elucidate the functions and clinical relevance of sodium-glucose cotransporter 2 (SGLT2) in resected lung adenocarcinoma.

Methods

The protein expression of SGLT2 in tumor samples from 199 patients with lung adenocarcinoma was analyzed by immunohistochemistry, and the protein expression, clinical variables, and survival outcomes were compared.

Results

The median SGLT2 expression was significantly higher in advanced-stage and more aggressive adenocarcinomas. Age ≥70 (p < 0.01), BI ≥600 (p < 0.01), PRDX4 <25 (p < 0.01), and SGLT2 ≥12% (p = 0.03) were significant factors for RFS in multivariate analysis. Significant differences were observed in the RFS rates of the groups divided using the cutoff value of SGLT2 ≥12% (5-year RFS: 72.6% vs. 90%) (p < 0.01).

Conclusion

The expression of SGLT2 was more frequently detected in advanced-stage and more aggressive adenocarcinomas with aggressive biological behavior than in their counterparts. The survival analysis revealed that the strong expression of SGLT2 was associated with poorer RFS. The SGLT2 expression predicts postoperative recurrence in lung adenocarcinoma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAdenocarcinoma of LungSodium-Glucose Transporter 2HumansMaleFemaleAgedMiddle AgedAged, 80 and overAdenocarcinomaBiomarkers, TumorAdultPrognosisImmunohistochemistryNeoplasm StagingNeoplasm Recurrence, LocalClinical Relevance

Stichwörter der Autor:innen

AdenocarcinomaLungPrognosisSGLT2Surgery

Substanzen

Sodium-Glucose Transporter 2SLC5A2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Kanazawa Medical University, Uchinada-machi, Japan.
  • Imamitsu Home Care Clinic, Kitakyushu, Japan.
  • Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Uchinada-machi, Japan.

Zitieren

APA

Iwai, S., Motono, N., Oyama, T., Shioya, A., Yamada, S., & Uramoto, H. (2024). The Clinical Relevance of the Expression of SGLT2 in Lung Adenocarcinoma. Oncology, 102(8), 710-719. https://doi.org/10.1159/000536060

Vancouver

Iwai S, Motono N, Oyama T, Shioya A, Yamada S, Uramoto H. The Clinical Relevance of the Expression of SGLT2 in Lung Adenocarcinoma. Oncology. 2024;102(8):710-719. doi:10.1159/000536060

BibTeX
@article{Iwai2024,
  author = {Iwai, Shun and Motono, Nozomu and Oyama, Tsunehiro and Shioya, Akihiro and Yamada, Sohsuke and Uramoto, Hidetaka},
  title = {The Clinical Relevance of the Expression of SGLT2 in Lung Adenocarcinoma},
  journal = {Oncology},
  year = {2024},
  volume = {102},
  number = {8},
  pages = {710--719},
  doi = {10.1159/000536060}
}
Kostenlos starten →